10X Genomics Inc TXG

$93.50 +4.74 (5.34%)

Valuation

Market cap
11,564,630,000
Revenue TTM
$642,820,000
Net income TTM
$-43,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-6.77%
Debt to equity
0.00

Trading

Volume
3,147,200
Avg volume
3,030,618
Day's range
$88.14 – $94.56
Shares out
130,291,000
Stochastic %K
92%
Beta
1.99
Analysts
Sell
Price target
$64.12

Price

Company profile

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromiu...

Show more

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Industry
Medical Devices
Sector
Healthcare
Phone
925 401 7300
Website
https://www.10xgenomics.com
Address
6230 Stoneridge Mall Road, Pleasanton, United States

Latest news

No headlines yet.

Stocktwits

WOLFSTREET Oct 3, 1:57 AM
$TXG That was CC 9.4, go ahead and ignore that outdated format although it laid plenty of foundation for what C² 9.9 is today. Five revisions later and C² is like Arnold ready for Mr. Olympia contest. Bottom line, 650% GAINS, Massive Upside all shared right here in real time for those who believe, had patience, and showed some decent level of intelligence. Did you know C² requires very minimal intelligence from its users? They do not need to draw silly lines, make stupid assumptions, follow analysts, and waste time and money.
0 replies
WOLFSTREET Oct 3, 1:49 AM
$TXG Well, official C² 9.9 is out and working very nicely! As part of 9.9, the last BETA feature is now proven and embedded throughout the platform, while a new "AI" feature is introduced. This one just made it under the wire and will be tested until C² X comes out Jan 1 2027. C² X is already road-mapped and will be ready for 2027 new year. So AI is not only accelerating the C² development cycles, but what happens when we point AI to the C² DATA Repository? The answer is what I discovered and was able to get into release 9.9. It effectively reduces the C² data package eval time from 60 seconds to under 5 seconds! After using it for a few weeks, I can tell you it is way faster and better than I. The new C² AI Jedi Master is not yet contributing to the LISTING agent, that is part of C² X road map once AI Jedi completes full testing.
0 replies
iQuicky Oct 2, 6:02 PM
$TXG bright star
0 replies
bidenomics_man Oct 1, 5:23 PM
$SDEV you may not have been able to short this, but you can still short $TXG
0 replies
bidenomics_man Oct 1, 4:42 PM
$TXG short, nothing lasts forever
1 replies
Gostrongx Sep 30, 8:27 PM
$CRSP $TXG CRSP been sitting in the 50’s for months and TXG is on fire Do something CRSP!
0 replies
STRelativeStrength Sep 30, 7:20 PM
$TXG undiscovered breakout with 2996 watchers
1 replies
Stocktwits52wHighs Sep 30, 7:16 PM
$TXG printed a new 52-week high today
0 replies